FindTrial
Sign In

Clinical Value of CA 19-9 with Reference to the Lewis Blood Group Status for Prediction of Benign and Malignant Obstructive Jaundice

Clinical Value of CA 19-9 with Reference to the Lewis Blood Group Status for Prediction of Benign and Malignant Obstructive Jaundice : A prospective Analytical Study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
TCTR
Registry ID
TCTR20160927002
Enrollment
Unknown
Registered
2016-09-27
Start date
2016-11-01
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obstructive jaundice CA 19&#45

Interventions

A group of obstructive jaundice patients whom blood sample will be collected to test for CA 19&#45
9 and Lewis blood group.
Diagnostic
CA 19&#45
9&#45
Lewis group

Sponsors

The Thailand Research Fund (TRF)
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: - Obstructive jaundice patients whose common bile duct dilates 8 mm or more and has a conjugated hyperbilirubinemia who will undergo ERCP

Exclusion criteria

Exclusion criteria: - History of biliary drainage - Cirrhosis

Design outcomes

Primary

MeasureTime frame
sensitivity, specificity, positive predictive value, negative predictive value and accuracy of CA 19 Immediately after definite diagnosis Standard calculation—

Secondary

MeasureTime frame
- - -—

Countries

Thailand

Contacts

Public ContactNonthikorn Theerasuwipakorn

King Chulalongkorn Memorial Hospital

knenous_demilune@hotmail.com0897982954

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026